Insilico Medicine, SK Biopharmaceuticals strike $2.5B AI drug discovery deal targeting neuroimmune therapies

“We want to be the SpaceX of the pharmaceutical industry,” Alex Zhavoronkov, co-CEO of Insilico Medicine tells Fortune.